Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: BRAVEHEART who wrote (412)	12/30/1998 6:09:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 1494

Okay, last chance to load up before the ask starts it's upward climb from 50 cents. Of course, it might be prudent to subscribe to the Neuroinvestment newsletter before taking this too seriously. Up til know I've been playing with money made from the hot stock market last spring, daytrades, a couple pump and dumps etc. That is, I'm playing with money that just fell into my lap...a nice way to play, if a bit reckless. If there are any newbies to the thread, I think I had a couple facts wrong in recent posts, here is the last PR from ntii which states progress very clearly. biz.yahoo.com ''Thanks to our collaborative relationships, the clinical development of Memantine has entered an important new phase,'' said Paul E. Freiman, president and chief executive officer of NTI. ''This Phase IIB trial in diabetic patients was partially funded through payments previously received from our strategic partner, Merz + Co. GmbH & Co. of Frankfurt, Germany. Merz is currently conducting Phase III human clinical trials of Memantine for senile dementia and Alzheimer's disease. Finally, in association with NTI, the AIDS Clinical Trials Group of the National Institutes of Health is conducting a Phase II trial of Memantine for the treatment of AIDS dementia syndrome, which is coming close to final patient enrollment.'' --mike